Acticor Biotech is a clinical stage biopharmaceutical company,a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.

In May 2022, Acticor Biotech presented positive results from its Phase 1b/2a study, ACTIMIS, confirming the safety profile and showing a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke.
The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 400 patients, with clinical results expected in Q2 2024.

Glenzocimab is a humanized monoclonal antibody fragment (fab) directed against the human platelet glycoprotein GPVI, and a novel antithrombotic drug developed by Acticor-Biotech. Glenzocimab is being developed for use during the acute phase of ischemic stroke as an add-on therapy to thrombolysis, with or without mechanical thrombectomy.

Moreover, since 2020, the action of glenzocimab has also been explored regarding the treatment of Acute Respiratory Distress Syndrome (ARDS) in patients infected with SARS-Cov-2.

–  Therapeutic areas: Cardiovascular emergencies, Acute ischemic stroke

–  Based in: Paris (FRANCE) dedicated external team in US territory

–  Employees: 11 – 50

–  Created in: 2013